BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld Asia
Home
» CFDA gives fast track status to Jiangsu Nhwa for modified anti-epilepsy drug
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CFDA gives fast track status to Jiangsu Nhwa for modified anti-epilepsy drug
June 11, 2014
By
Shannon Ellis
No Comments
SHANGHAI – Jiangsu Nhwa Pharmaceutical Co. Ltd.'s DP-VPA, a modified valproic acid (VPA) treatment for epilepsy, has received fast track status from the CFDA.
BioWorld Asia